These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30314826)

  • 1. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
    Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B
    J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
    Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
    Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
    Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.
    Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS
    BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
    Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
    Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea for the treatment of sickle cell disease.
    Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
    Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
    Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
    BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
    Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
    Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.
    Oyeku SO; Driscoll MC; Cohen HW; Trachtman R; Pashankar F; Mullen C; Giardina PJ; Velazco N; Racine AD; Green NS
    Pediatr Blood Cancer; 2013 Apr; 60(4):653-8. PubMed ID: 23129068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.
    van Geyzel L; Arigliani M; Inusa B; Singh B; Kozlowska W; Chakravorty S; Bossley CJ; Ruiz G; Rees D; Gupta A
    Arch Dis Child; 2020 Jun; 105(6):575-579. PubMed ID: 31871045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
    Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease.
    LaVista JM; Treise DM; Dunbar LN; Ritho J; Hartzema AG; Lottenberg R
    J Natl Med Assoc; 2009 Mar; 101(3):251-7. PubMed ID: 19331257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A; Jerrell JM; Stallworth JR
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease.
    Jabour SM; Beachy S; Coburn S; Lanzkron S; Eakin MN
    J Racial Ethn Health Disparities; 2019 Dec; 6(6):1233-1243. PubMed ID: 31410784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
    Lanzkron S; Haywood C; Segal JB; Dover GJ
    Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.